|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1990-3-28
|
|
pubmed:abstractText |
Expression of human immunodeficiency virus type 1 structural proteins requires both the viral Rev trans-activator and its cis-acting RNA target sequence, the Rev response element (RRE). The RRE has been mapped to a conserved region of the HIV-1 env gene and is predicted to form a complex, highly stable RNA stem-loop structure. Site-directed mutagenesis was used to define a small subdomain of the RRE, termed stem-loop II, that is essential for biological activity. Gel retardation assays demonstrated that the Rev trans-activator is a sequence-specific RNA binding protein. The RRE stem-loop II subdomain was found to be both necessary and sufficient for the binding of Rev by the RRE. We propose that the HIV-1 Rev trans-activator belongs to a new class of sequence-specific RNA binding proteins characterized by the presence of an arginine-rich binding motif.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Gene Products, rev,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotide Probes,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Trans-Activators,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Structural Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/rev Gene Products, Human...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0092-8674
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
23
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
675-83
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:2406030-Animals,
pubmed-meshheading:2406030-Base Sequence,
pubmed-meshheading:2406030-Cell Line,
pubmed-meshheading:2406030-Cloning, Molecular,
pubmed-meshheading:2406030-DNA, Viral,
pubmed-meshheading:2406030-Gene Products, rev,
pubmed-meshheading:2406030-Genes, Viral,
pubmed-meshheading:2406030-HIV-1,
pubmed-meshheading:2406030-Molecular Sequence Data,
pubmed-meshheading:2406030-Mutation,
pubmed-meshheading:2406030-Nucleic Acid Conformation,
pubmed-meshheading:2406030-Oligonucleotide Probes,
pubmed-meshheading:2406030-RNA, Viral,
pubmed-meshheading:2406030-Trans-Activators,
pubmed-meshheading:2406030-Transcription, Genetic,
pubmed-meshheading:2406030-Viral Structural Proteins,
pubmed-meshheading:2406030-Virus Replication,
pubmed-meshheading:2406030-rev Gene Products, Human Immunodeficiency Virus
|
|
pubmed:year |
1990
|
|
pubmed:articleTitle |
HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence.
|
|
pubmed:affiliation |
Howard Hughes Medical Institute, Department of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina 27710.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
